Cadian Capital Management, LP Amicus Therapeutics, Inc. Transaction History

Cadian Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$6.63 - $11.16 $9.21 Million - $15.5 Million	-1,389,344 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$7.48 - $10.75 $2.91 Million - $4.19 Million	389,344 Added 38.93%	1,389,344 $13.5 Million
Q3 2019 Nov 13, 2019	BUY	$8.02 - $13.25 $3.21 Million - $5.3 Million	400,000 Added 66.67%	1,000,000 $8.02 Million
Q2 2019 Aug 13, 2019	BUY	$10.96 - $14.4 $4.38 Million - $5.76 Million	400,000 Added 200.0%	600,000 $7.49 Million
Q1 2019 May 14, 2019	BUY	$10.04 - $13.92 $2.01 Million - $2.78 Million	200,000 New	200,000 $2.72 Million
Q4 2017 Feb 13, 2018	SELL	$12.51 - $16.24 $5 Million - $6.5 Million	-400,000 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$11.74 - $15.78 $4.7 Million - $6.31 Million	400,000	400,000 $6.03 Million

311

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.69B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Cadian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cadian Capital Management, LP with notifications on news.